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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERThe Left Atrium and Prognosis 493Brian D. Hoit
In this state-of-the-art paper, Hoit reviews the methods used to assess left atrial size and
function, and discuss their role in predicting cardiovascular events in general and referral
populations, and in patients with atrial ﬁbrillation, cardiomyopathy, ischemic heart disease,
and valvular heart disease.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYDual Antiplatelet Therapy Duration and In-Stent Restenosis 506
Gianluca Campo, Matteo Tebaldi, Pascal Vranckx, Simone Biscaglia, Carlo Tumscitz,
Roberto Ferrari, Marco Valgimigli
This study investigates the clinical outcome of patients treated with percutaneous coronary
intervention (PCI) for in-stent restenosis (ISR) randomized to a short (6 months) versus long
(24 months) dual antiplatelet therapy (DAPT) regimen. A total of 224 patients undergoing a
PCI procedure for ISR who were enrolled in the PRODIGY trial were randomized to a short
versus long DAPT regimen. The primary objective was the cumulative incidence of death,
nonfatal myocardial infarction, or cerebrovascular accident at 24 months. Overall,
114 patients were allocated to the short DAPT regimen and 110 patients to the long DAPT
regimen. The cumulative incidence of the primary endpoint at 24 months was 16.7% in
the short DAPT regimen group compared with 7.3% in the long DAPT regimen group.
This was principally due to a lower occurrence of death in the long DAPT regimen group as
compared with the short DAPT regimen group (3.5% vs. 10.5%). There was no difference in
the occurrence of bleeding complications between the long and short DAPT regimen groups.
This study provides preliminary evidence that patients undergoing a new PCI procedure for
ISR may beneﬁt from long-term administration of aspirin plus clopidogrel.(continued on page A-26)
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Leor Perl, Hila Lerman-Shivek, Eldad Rechavia, Muthiah Vaduganathan, Dorit Leshem-Lev,
Noa Zemer-Wassercug, Oshrat Dadush, Pablo Codner, Tamir Bental, Alexander Battler,
Ran Kornowski, Eli I. Lev
Despite better clinical efﬁcacy of prasugrel compared with clopidogrel, antiplatelet response
to prasugrel is not uniform. The objective of this study was to determine whether response to
prasugrel is associated with the proportion of circulating reticulated platelets (RPs) in patients
with ST-segment elevation myocardial infarction (STEMI). A total of 62 patients (mean age
57  8 years, 21% women, 28% with diabetes) with STEMI and treated with primary
percutaneous intervention (PCI) and prasugrel were included. At early time points
(2 to 4 days), RP levels were strongly correlated with platelet reactivity when evaluated by the
VerifyNow assay (Accumetrics, San Diego, California) and Multiplate analyzer (Dynabyte,
Munich, Germany). The upper tertile of RPs displayed higher platelet reactivity compared
with the middle and lower tertiles. Similar strong correlations between RPs and platelet
reactivity were noted at 30 days post-PCI. The study concludes that circulating RPs strongly
correlate with response to prasugrel in patients with STEMI treated with PCI. High levels of
RPs are associated with increased platelet reactivity despite prasugrel treatment.
Editorial Comment: Laurent Bonello, Corinne Frère, Franck Paganelli, Marc Laine, p. 518CARDIOMETABOLIC RISKLp(a) in Coronary Artery Disease 520
Michelle L. O’Donoghue, David A. Morrow, Sotirios Tsimikas, Sarah Sloan, Angela F. Ren,
Elaine B. Hoffman, Nihar P. Desai, Scott D. Solomon, Michael Domanski, Kiyohito Arai,
Stephanie E. Chiuve, Christopher P. Cannon, Frank M. Sacks, Marc S. Sabatine
The objective of this study was to assess the prognostic utility of lipoprotein(a) [Lp(a)] in
individuals with coronary artery disease (CAD). Plasma Lp(a) was measured in 6,762 subjects
across 3 studies of patients with CAD. The data were then combined with previously
published reports. Across the 3 combined studies, increasing levels of Lp(a) were not
associated with the risk of cardiovascular (CV) events when modeled as a continuous variable
or by a quintile of Lp(a). When data were combined with previously published studies of
Lp(a) in secondary prevention, and results were stratiﬁed on the basis of total cholesterol
(TC), the association between Lp(a) and CV events was signiﬁcant in studies in which
average TC was 240 mg/dl, whereas this relationship was not apparent for studies with
average an TC of <240 mg/dl. The ﬁndings from the current study do not support the
routine use of Lp(a) as a marker for risk assessment in individuals with CAD whose TC is
not high. By contrast, very elevated levels of Lp(a) may help to identify an increased risk of
CV events in patients with CAD whose TC is 240 mg/dl.(continued on page A-27)
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Hiromichi Ohmura, Toru Yakushigawa, Hatsumi Sugiyama, Yasushi Shimada,
Youichi Nojima, Nobuo Shio
The objective of this study was to assess whether spironolactone treatment reduced
cardiovascular and cerebrovascular (CCV) morbidity and mortality in hemodialysis (HD)
patients. Of 309 oligoanuric HD patients, 157 were randomly assigned to receive 25 mg/day
of spironolactone. Primary outcome was composite of death or hospitalization from CCV
events, and secondary outcome was death from all causes. During the 3-year follow-up, the
primary outcome occurred in 5.7% of patients in the treatment group and 12.5% of patients
in the control group. The secondary outcome was also signiﬁcantly reduced in the treatment
group as compared with controls. Gynecomastia or breast pain was reported in 16 patients,
and serious hyperkalemia leading to treatment discontinuation occurred in 3 patients. The
study concludes that aldosterone receptor blockade using spironolactone may substantially
reduce the risk of both CCV morbidity and death among HD patients.
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Thomas M. Maddox, Paul S. Chan, John A. Spertus, Fengming Tang, Phil Jones, P. Michael Ho,
Steven M. Bradley, Thomas T. Tsai, Deepak L. Bhatt, Pamela N. Peterson
This study assesses practice variation of secondary prevention medication prescription among
coronary artery disease (CAD) patients treated in outpatient practices. All patients were part
of a national outpatient cardiology practice registry (National Cardiovascular Disease
Registry–Pinnacle). The use of beta-blockers, angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers, and statins was evaluated. Among the 56,145 CAD patients in
58 practices, 103,830 (67%) were prescribed the optimal combination of medications for
which they were eligible. After adjustment for patient factors, the practice median rate ratio
for prescription was 1.25, indicating a 25% likelihood that 2 random practices would differ in
treating identical CAD patients. The authors conclude that among a national registry of
CAD patients treated in outpatient cardiology practices, over one-third of patients failed to
receive their optimal combination of secondary prevention medications.
Editorial Comment: L. Kristin Newby, p. 547(continued on page A-28)
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Roos F. J. Marsman, Connie R. Bezzina, Fabian Freiberg, Arie O. Verkerk, Michiel E. Adriaens,
Svitlana Podliesna, Chen Chen, Bettina Purfürst, Bastian Spallek, Tamara T. Koopmann, Istvan Baczko,
Cristobal G. dos Remedios, Alfred L. George, Jr, Nanette H. Bishopric, Elisabeth M. Lodder,
Jacques M. T. de Bakker, Robert Fischer, Ruben Coronel, Arthur A. M. Wilde, Michael Gotthardt,
Carol Ann Remme
A recent genome-wide association study (GWAS) for ventricular ﬁbrillation (VF) during
acute myocardial infarction has led to the identiﬁcation of a locus on chromosome 21q21 in
the vicinity of the CXADR gene. CXADR encodes the coxsackie and adenovirus receptor
(CAR); however, the role of CAR in ventricular conduction and arrhythmogeneity is
unknown. This study investigated the modulatory effect of CAR on ventricular conduction
and arrhythmia vulnerability in the setting of myocardial ischemia. Evaluation of human left
ventricular samples reveals that the risk allele at the chr21q21 GWAS locus was associated
with lower CXADR messenger ribonucleic acid levels, suggesting that decreased cardiac
levels of CAR predispose to ischemia-induced VF. Hearts from CAR+/ mice displayed
ventricular conduction slowing in addition to an earlier onset of ventricular arrhythmias
during the early phase of acute myocardial ischemia following left anterior descending
coronary artery ligation. Patch-clamp analysis of isolated CAR+/ myocytes showed reduced
sodium current magnitude speciﬁcally at the intercalated disc. Further analysis revealed that
CAR affects sodium channel function through a physical interaction with the cardiac sodium
channel protein NaV1.5. The authors have identiﬁed CAR as a novel modiﬁer of ventricular
conduction and arrhythmia vulnerability in the setting of myocardial ischemia.
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Leeanne Grigg, James M. Ramsay, Gavin R. Wheaton, Sarah Hope, Michael H. Cheung,
Christian P. Brizard
This study reports on the long-term outcome of transatrial repair of tetralogy of Fallot. The
records of 675 consecutive patients undergoing transatrial repair of tetralogy of Fallot
between 1980 and 2005 were reviewed. Median age of repair was 2 years in the ﬁrst 8 years
and 1 year from 1988 onwards. There were 7 hospital deaths (1%), and 8 patients died during
follow-up (2 sudden unexpected and 6 noncardiac deaths). The 25-year survival was 97%.
The 25-year freedom from implantation of a valve conduit was 84.6%. Multivariable analysis
revealed that prior palliation and younger age at repair were predictive of implantation of a
valve conduit (hazard ratios: 2.4 and 0.7, respectively). The authors conclude that during
long-term follow-up, transatrial repair of tetralogy of Fallot was associated with minimal risk
of sudden death and low rate of reintervention for right ventricular dilation and residual
outﬂow tract obstruction.
